Recently, several studies have been carried about maintenance therapy in non-small cell lung cancer, and some chemotherapy agents have been approved for clinical practice. But there are still a lot of questions about maintenance therapy that we have to consider. For example, the defects of design in maintenance therapy trials; how to choose gold standard of maintenance therapy for evaluation; who benefit from the maintenance therapy and how to estimate pharmaceutical economics. In this paper, we will make deep analysis about these issues
Abstract: Until recently standard first-line treatment for advanced non-small cell lung cancer (NSCL...
Highlights 1. Maintenance therapy extended PFS and OS of patients with NSCLC. 2. MT with targeted dr...
Lung cancer has become the leading cause of cancer deaths, with nonsmall cell lung cancer (NSCLC) ac...
Maintenance therapy is emerging as a treatment strategy in the management of advanced non small cell...
Maintenance therapy is emerging as a treatment strategy in the management of advanced non small cell...
Abstract:Maintenance therapy for patients with advanced non-small cell lung cancer has been an area ...
Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the industrialized world....
Although current recommendations for the treatment of advanced non-small cell lung cancer (NSCLC) in...
Maintenance therapy for patients with advanced non-small cell lung cancer has been an area of intens...
Abstract: Maintenance therapy for advanced nonsmall cell lung cancer has shown some clinical benefit...
Maintenance chemotherapy has a long history of use in hematologic malignancies, in which the benefit...
Treatment of lung cancer had evolved during the last decade with the introduction of new chemotherap...
AbstractNon-small cell lung cancer (NSCLC) is the leading cause of cancer death in the industrialize...
Lung cancer is one of the common malignant tumors in the world, the incidence of small cell lung can...
Abstract: Although progress could have been achieved in treatment of patients with advanced non-smal...
Abstract: Until recently standard first-line treatment for advanced non-small cell lung cancer (NSCL...
Highlights 1. Maintenance therapy extended PFS and OS of patients with NSCLC. 2. MT with targeted dr...
Lung cancer has become the leading cause of cancer deaths, with nonsmall cell lung cancer (NSCLC) ac...
Maintenance therapy is emerging as a treatment strategy in the management of advanced non small cell...
Maintenance therapy is emerging as a treatment strategy in the management of advanced non small cell...
Abstract:Maintenance therapy for patients with advanced non-small cell lung cancer has been an area ...
Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the industrialized world....
Although current recommendations for the treatment of advanced non-small cell lung cancer (NSCLC) in...
Maintenance therapy for patients with advanced non-small cell lung cancer has been an area of intens...
Abstract: Maintenance therapy for advanced nonsmall cell lung cancer has shown some clinical benefit...
Maintenance chemotherapy has a long history of use in hematologic malignancies, in which the benefit...
Treatment of lung cancer had evolved during the last decade with the introduction of new chemotherap...
AbstractNon-small cell lung cancer (NSCLC) is the leading cause of cancer death in the industrialize...
Lung cancer is one of the common malignant tumors in the world, the incidence of small cell lung can...
Abstract: Although progress could have been achieved in treatment of patients with advanced non-smal...
Abstract: Until recently standard first-line treatment for advanced non-small cell lung cancer (NSCL...
Highlights 1. Maintenance therapy extended PFS and OS of patients with NSCLC. 2. MT with targeted dr...
Lung cancer has become the leading cause of cancer deaths, with nonsmall cell lung cancer (NSCLC) ac...